Salomon M. Stemmer, Nebojsa S. Manojlovic, Mihai Vasile Marinca, Petar Petrov, Nelly Cherciu, Doina Ganea, Tudor Eliade Ciuleanu, Ioana Adriana Pusca, Muhammad Shaalan Beg, William T. Purcell, Adina-Emilia Croitoru, Rumyana Nedyalkova Ilieva,

Cancers 2021, 13, 187(75)

Pnina Fishman, Shira Cohen, Inbal Itzhak, Johnny Amer, Ahmad Salhab, Faina Barer, Rifaat Safadi. The A3 adenosine receptor agonist, namodenoson, ameliorates non?alcoholic steatohepatitis in mice.,

International Journal of Molecular Medicine 44: 2256-2264(74)

Cohen S, Fishman P. Targeting the A3 adenosine receptor to treat cytokine release syndrome in cancer immunotherapy.

Development and Therapy. 2019:13 491–497(73)

Cohen S, Barer F, Itzhak I, Silverman MH, Fishman P. Inhibition of IL-17 and IL-23 in Human Keratinocytes by the A3 Adenosine Receptor Agonist Piclidenoson.

J Immunol Res. 2018 May 15;2018:2310970(72)

Ohana G, Cohen S, Rath-Wolfson L, Fishman P. A3 adenosine receptor agonist, CF102, protects against hepatic ischemia/reperfusion injury following partial hepatectomy.

Mol Med Rep. 2016 Nov;14(5):4335-4341(71)

David M, Gospodinov DK, Gheorghe N, Mateev GS, Rusinova MV, Hristakieva E, Solovastru LG, Patel RV, Giurcaneanu C, Hitova MC, Purcaru AI, Horia B, Tsingov II, Yankova RK, Kadurina MI, Ramon M, Rotaru M, Simionescu O, Benea V, Demerdjieva ZV,

J Drugs Dermatol. 15(8):931-8(70)

Fishman P and Cohen S. The A3 adenosine receptor (A3AR): therapeutic target and predictive biological marker in rheumatoid arthritis.

Clin Rheumatol, 2016; 35(9):2359-62(69)

Rumen M Stoilov, Rodina N Licheva, Mariyana K Mihaylova, Tatiana Reitblat, Emil A Dimitrov, Krasimira M Shimbova, Girish Bhatia, Ameet Pispati, Alexandra Gurman- Balbir, BR Bagaria, Boytcho Aleksandrov Oparanov, Sari Fishman, Zivit Harpaz,

Immunome Res 2014, 11:1(68)

Pnina Fishman. Adenosine Receptors – The Promise of A3AR Research.

Drug Development & Delivery March, 2015 Vol 15 No 1(67)

Cohen S, Barer F, Bar-Yehuda S, IJzerman AP, Jacobson KA, Fishman P. A3 adenosine receptor allosteric modulator induces an anti-inflammatory effect: in vivo studies and molecular mechanism of action.

Mediators Inflamm. 2014;2014:708746. doi: 10.1155/2014/708746. Epub 2014(66)

Pnina Fishman, Shira Cohen, Sara Bar Yehuda. Targeting the A3 adenosine receptor for glaucoma treatment (Review).

Molecular Medicine Reports. DOI: 10.3892/mmr.2013.1413(65)

Stemmer M, Benjaminov F, Medalia G, Ciuraru NB, Silverman MH, Bar-Yehuda S, Fishman S, Harpaz Z, Farbstein M, Cohen S, Patoka R, Singer B, Kerns WD, Fishman P. CF102 for the Treatment of Hepatocellular Carcinoma: A Phase I/II, Open-Label, Dose-Escalation

The Oncologist. 18:25-26, 2013 Online version(64)

Pnina Fishman, Sara Bar-Yehuda, Bruce T. Liang and Kenneth A. Jacobson. Pharmacological and therapeutic effects of A3 adenosine receptor agonists.

Drug Discov Today. 2012;17(7-8):359-66(63)

Clara C. Blad, Jacobien K. von Frijtag Drabbe Künzel, Henk de Vries, Thea Mulder-Krieger, Sara Bar-Yehuda, Pnina Fishman, Adriaan P. IJzerman. Putative role of the adenosine A3 receptor in the antiproliferative action of N6-(2-isopentenyl)adenosine.

Purinergic Signal, 2011(62)

Sara Bar-Yehuda, Dror Luger, Avivit Ochaion, Shira Cohen, Renana Patokaa, Galina Zozulya, Phyllis B. Silver, Jose Maria Garcia Ruiz De Morales, Rachel R. Caspi, Pnina Fishman. Inhibition of experimental auto-immune uveitis by the A3 adenosine receptor ago

Int J Mol Med. Nov;28(5):727-3, 2011(61)

Ashar JN, Mathur A, Sangwan V. Avni I, Sliverman MH, Bar Yehuda S, Fishman P. CF101 for dry eye.

Ophthalmology. 118:1011-1012, 2011(60)

David M, Akerman L, Ziv M, Kadurina M, Gospodinov D, Pavlotsky, Yankova R, Kouzeva V, Ramon M, Silverman MH, Fishman P. Treatment of plaque-type psoriasis with oral CF101: data from an exploratory randomized phase 2 clinical trial.

Journal of the European Academy of Dermatology and Venereology, 2011(59)

Cohen S, Stemmer SM,Zozulya G, Ochaion A, Patoka R, Barer F, Bar-Yehuda S, Rath-Wolfson L, Jacobson KA, Fishman P. CF102 an A3 adenosine receptor agonist mediates anti-tumor and anti-inflammatory effects in the liver.

Journal of Cellular Physiology, 226:2438-2447, 2011(57)

I. Avni, H. Garzozi, I. Barequet, F. Segev, D. Varssano, G. Sartani, N. Chetrit, E. Bakshi, D. Zadok, O. Tomkins, G. Litvin, K. Jacobson, S Fishman, Z. Harpaz, M. Farbstein, S. Bar Yehuda, M. Silverman, W. Kerns, D. Bristol, I Cohn, P. Fishman.

Ophthalmology , 117:1287-1293, 2010(56)

Fishman, P., Bar-Yehuda, S., Varani, K., Gessi, S., Merighi, S., and Borea, PA. Agonists and Antagonists: Molecular Mechanisms and Therapeutic Applications. In: P.A. Borea (ed.), A3 Adenosine Receptors from Cell Biology to Pharmacology and Therapeutics.

Fishman, P., Bar-Yehuda, S. Rheumatoid Arthritis: History, Molecular Mechanisms and Therapeutic Applications. P.A. Borea (ed.), A3 Adenosine Receptors from Cell Biology to Pharmacology and Therapeutics.

S. Bar-Yehuda, L. Rath-Wolfson, L. Del Valle, A. Ochaion, S. Cohen, R. Patoka, G. Zozulya, F. Barer, E. Atar, S. Pina-Oviedo, G. Perez-Liz, D. Castel,

ARTHRITIS & RHEUMATISM Vol. 60, No. 10, (2009) 3061–3071(53)

P. Fishman, S. Bar-Yehuda, M. Synowitz, J.D. Powell, K.N. Klotz, S. Gessi, and P.A. Borea. Adenosine Receptors and Cancer.

Handbook of Experimental Pharmacology 193 (2009) 399-441(52)

A. Ochaion A, Bar-Yehuda S, Cohen S, Amital H, Jacobson KA, Joshi BV, Gao ZG, Barer F, Patoka R, Del Valle L, Perez-Liz G, Fishman P. The anti-inflammatory target A3 adenosine receptor is over-expressed in rheumatoid arthritis,

Cellular Immunology 258 (2009) 115–122(51)

Bar-Yehuda S., Stemmer S.M., Madi L., Castel D., Ochaion A., Cohen S., Barer F., Zabutti A., Perez-Liz G., Del Valle L., Fishman P. The A3 adenosine receptor agonist CF102 induces apoptosis of hepatocellular carcinoma via de-regulation of the

Int J Onc 33: 287-295, 2008(50)

Ochaion A, Bar-Yehuda S, Cohen S, Amital H, Jacobson KA, Joshi BV, Gao ZG, Barer F, Patoka R, Del Valle L, Perez-Liz G, Fishman P. The A3 adenosine receptor agonist CF502 inhibits the PI3K, PKB/Akt and NF-kappaB signaling pathway in synoviocytes from

Biochem Pharmacol. 2008 ;76(4):482-94(49)

Silverman M. H., Strand V., Markovits D., Nahir M., Reitblat T., Molad Y., Rosner I, Rozenbaum M., Mader R., Adawi M., Caspi D., Tishler M., Langevitz P., Rubinow A., Friedman J., Green L., Tanay A., Ochaion A., Cohen S., Kerns W. D., Cohn I.,

The Journal of Rheumatology 2008;35(1):41-8(48)

Bar Yehuda S., Silvermen M., Kerns W., Ochaion, A., Cohen, S., Fishman, P. The Anti-inflammatory Effect of A3 Adenosine Receptor Agonists: A Novel Targeted Therapy for Rheumatoid Arthritis.

Expert Opin. Investig. Drugs (2007) 16(10):1601-1613(47)

Fishman P., Jacobson KA., Ochaion A., Cohen S., Bar Yehuda S. The Anti-Cancer Effect of A3 Adenosine Receptor Agonists: A Novel Targeted Therapy.

Immun, Endoc. & Metab. Agents in Med Chem. 7:298-303, 2007(46)

Madi L., Cohn, S. Ochaion A., Bar-Yehuda S., Barer F., Fishman P. Over-expression of A3 Adenosine Receptor in PBMNC of Rheumatoid Arthritis Patients: Involvement of NF-kB in mediating Receptor Level.

J. Rheumatology. 34:20-26, 2007(45)

Fishman, P., Bar-Yehuda, S., Madi, L. In: Adenosine, Tumors, and Immunity. ADENOSINE RECEPTORS: Therapeutic Aspects for Inflammatory and Immune Diseases.

Taylor&Francis; London. P: 299-312, 2007(44)

Ochaion A, Bar-Yehuda S, Cohn S, Del Valle L, Perez-Liz G, Madi L, Barer F, Farbstein M, Fishman-Furman S, Reitblat T, Reitblat A, Amital H, Levi Y, Molad Y, Mader R, Tishler M, Langevitz P, Zabutti A, Pnina Fishman. Methotrexate enhances the

Arthritis Research & Therapy 2006, 8:R169(43)

Rath-Wolfson L., Bar-Yehuda S. Madi L., Fishman P. IB-MECA, an A3 adenosine receptor agonist prevents bone resorption in rats with adjuvant induced arthritis.

Clin Exp Rheumatol. 2006; 24(4):400-6(42)

Fishman P., Bar-Yehuda S., Madi L., Rath-Wolfson L., Ochaion A., Cohen S. and Baharav E. The PI3K-NF-kB signal transduction pathway is involved in mediating the anti-inflammatory effect of IB-MECA in adjuvant induced arthritis.

Arthritis Research & Therapy 2006, 8:R33(41)

Bar-Yehuda, S., Madi,L., Silberman, D., Slosman G., Shkapenuk, M., Fishman, P. CF101, an Agonist to the A3 Adenosine Receptor Enhances the Chemotherapeutic Effect of 5-Flurouracil in a Colon Carcinoma Murine Model.

Neoplasia. 7:85-90. 2005(40)

Baharav, E., Bar-Yehuda, S., Madi, L., Silberman, D., Rath-Wolfson, L., Halpren, M., Ochaion, A., Weinberger, A., Fishman, P. The Anti-inflammatory Effect of A3 Adenosine Receptor Agonists in Murine Autoimmune Arthritis Models.

J Rheumatol. 32:469-76. 2005(39)

van Troostenburg, A. R., Clark, E. V., Carey, W. D. H., Warrington, S. J., Kerns, W.D., Cohn, I., Silverman, M. H., Bar-Yehuda, S., Fong, K.L. L., Fishman, P. Tolerability, pharmacokinetics, and concentration-dependent hemodynamic effects of oral CF101,

Int J Clin Pharmacol Ther. 42: 534-42, 2004(38)

Madi, L., Ochaion, A., Rath-Wolfson, L., Bar-Yehuda, S., Erlanger, A., Ohana, G., Harish, A., Merimski, O., Barer, F., Fishman, P. The A3 Adenosine Receptor is Highly Expressed in Tumor vs. Normal Cells: Potential Target for Tumor Growth Inhibition.

Clinical Cancer Research, 10: 4472-4479, 2004(37)

Fishman, P., Bar-Yehuda, S., Ohana, G., Ochaion, A., Engelberg, A., Barer, F., Madi, L. An agonist to the A3 adenosine receptor inhibits colon carcinoma growth in mice via modulation of GSK-3ß and NF-kB.

Oncogene, 23: 2465-2471, 2004(36)

Harish, A., Ohana, G., Fishman, P., Arnon, O., Bar-Yehuda, S. A3 Adenosine Receptor Agonist Potentiates Natural Killer Cell Activity.

International J Oncol, 23:1245-1249. 2003(35)

Ohana, G., Bar-Yehuda, S., Arich, A., Madi L., Dreznick Z., Silberman D., Slosman G., Volfsson-Rath, L., Pnina Fishman. Inhibition of primary colon carcinoma growth and liver metastasis by the A3 adenosine receptor agonist.

CF101. British J Cancer, 89: 155(33)

Madi, L., Bar-Yehuda, S., Barer, F., Ardon, E., Ochaion, A., Fishman, P. A3 adenosine receptor activation in melanoma cells: association between receptor fate and tumor growth inhibition.

JBC. 278:42121-42130, 2003(32)

Fishman, P., Bar-Yehuda, S., Rath-Wolfson, L., Ardon, E., Barrer, F., Ochaion, A., Madi, L. Targeting the A3 adenosine receptor for cancer therapy: inhibition of Prostate carcinoma cell growth by A3AR agonist.

Anticancer Res. 23:2077-2083, 2003(31)

Merimsky O, Madi L, Bar-Yehuda S, Fishman P : Modulation of the A3 adenosine receptor by low agonist concentration induced anti-tumor and myelostimulation effects.

Drug Dev Res. 58:386-389, 2003(30)

Fishman, P., Bar-Yehuda, S. Pharmacology and therapeutic applications of A3 receptor subtype.

Curr Top Med Chem. 3:463-469, 2003(29)

Baharav, E., Dubrosin, A., Fishman, P., Bar-Yehuda, S., Halpern, M., Weinberger, A. Suppression of experimental zymosan induced arthritis by intraperitoneal administration of adenosine.

Drug Dev Res. 57 :182-186, 2002(27)

Bar-Yehuda, S., Madi, L., Barak, D., Mittelman, M., Ardon, E., Ochaion, A, Cohn, S., Fishman, P. Agonists to the A3 adenosine receptor induce G-CSF production via NF-kappaB activation: a new class of myeloprotective agents.

Exp Hematol. 30:1390-1398, 2002(25)

Fishman, P., Bar-Yehuda, S., Madi, L., Cohn, I. A3 adenosine receptor as a target for cancer therapy.

Anti-cancer Drugs. 13:437-443, 2002(23)

Fishman, P., Madi, L., Bar-Yehuda, S., Barer, F., Del Valle, L., Khalili, K. Evidence for involvement of Wnt signaling pathway in IB-MECA mediated suppression of melanoma cells.

Oncogene 21:4060-4064, 2002(21)

Fishman, P., Bar-Yehuda, S., Barer, F., Madi, L., Multani, A.F, Pathak, S. The A3 adenosine receptor as a new target for cancer therapy and chemoprotection.

Exp Cell Res. 269: 230-236, 2001(19)

Ohana, G., Bar-Yehuda, S, Barer, F., Fishman, P. Differential effect of adenosine on tumor and normal cell growth: focus on the A3 adenosine receptor.

J Cell Physiol. 186: 19-23. 2001(17)

Fishman, P., Bar-Yehuda, S., Farbstein, T., Barer, F., Ohana, G. Adenosine acts as a chemoprotective agent by stimulating G-CSF production: a role for A1 and A3 adenosine receptors.

J Cell Physiol. 183: 393-398, 2000(16)

Fishman, P., Bar-Yehuda, S., Ohana, G., Pathak, S., Wasserman, L., Barer, F., Multani, A.F. Adenosine acts as an inhibitor of lymphoma cell growth: a major role for the A3 adenosine receptor.

Eur. J Cancer 36:1452-1458, 2000(14)

Bar-Yehuda, S., Barer, F., Volfsson, L., Fishman, P. Resistance of muscles to tumor metastasis: a role for A3 adenosine receptor agonists.

Neoplasia 3: 125-131, 2001(13)

Bar-Yehuda, S., Farbstein, T., Barer, F., Ohana, G., Fishman, P. Oral administration of muscle derived small molecules inhibits tumor spread while promoting normal cell growth in mice.

Clin. Exp. Metastasis 17:513-535, 1999(11)

Fishman, P., Bar-Yehuda, S., Vagman, L. Adenosine and other low molecular weight factors released by muscle cells inhibit tumor cell growth.

Cancer Res. 58:3181-3187, 1998(9)

Cohen-Aloro, D., Merimsky, O., Bar-Yehuda, S., Klein, B., Kayzer, S., Fishman, P. Mononuclear cells release low molecular weight factors with anti-cancer activity: A lower level of production by cells of cancer patients.

Int. J Oncol. 12:921-925, 1998.(7)

Djaldetti, M., Sredni, B., Zigelman, R., Verber, M., Fishamn, P. Muscle cells produce a low molecular weight factor with anti-cancer activity.

Clin Exp Metastasis 14:189-196, 1996.(1)

Scientific Publications

Salomon M. Stemmer, Nebojsa S. Manojlovic, Mihai Vasile Marinca, Petar Petrov, Nelly Cherciu, Doina Ganea, Tudor Eliade Ciuleanu, Ioana Adriana Pusca, Muhammad Shaalan Beg, William T. Purcell, Adina-Emilia Croitoru, Rumyana Nedyalkova Ilieva,

Pnina Fishman, Shira Cohen, Inbal Itzhak, Johnny Amer, Ahmad Salhab, Faina Barer, Rifaat Safadi. The A3 adenosine receptor agonist, namodenoson, ameliorates non?alcoholic steatohepatitis in mice.,

Cohen S, Fishman P. Targeting the A3 adenosine receptor to treat cytokine release syndrome in cancer immunotherapy.

Cohen S, Barer F, Itzhak I, Silverman MH, Fishman P. Inhibition of IL-17 and IL-23 in Human Keratinocytes by the A3 Adenosine Receptor Agonist Piclidenoson.

Ohana G, Cohen S, Rath-Wolfson L, Fishman P. A3 adenosine receptor agonist, CF102, protects against hepatic ischemia/reperfusion injury following partial hepatectomy.

David M, Gospodinov DK, Gheorghe N, Mateev GS, Rusinova MV, Hristakieva E, Solovastru LG, Patel RV, Giurcaneanu C, Hitova MC, Purcaru AI, Horia B, Tsingov II, Yankova RK, Kadurina MI, Ramon M, Rotaru M, Simionescu O, Benea V, Demerdjieva ZV,

Fishman P and Cohen S. The A3 adenosine receptor (A3AR): therapeutic target and predictive biological marker in rheumatoid arthritis.

Rumen M Stoilov, Rodina N Licheva, Mariyana K Mihaylova, Tatiana Reitblat, Emil A Dimitrov, Krasimira M Shimbova, Girish Bhatia, Ameet Pispati, Alexandra Gurman- Balbir, BR Bagaria, Boytcho Aleksandrov Oparanov, Sari Fishman, Zivit Harpaz,

Pnina Fishman. Adenosine Receptors – The Promise of A3AR Research.

Cohen S, Barer F, Bar-Yehuda S, IJzerman AP, Jacobson KA, Fishman P. A3 adenosine receptor allosteric modulator induces an anti-inflammatory effect: in vivo studies and molecular mechanism of action.

Pnina Fishman, Shira Cohen, Sara Bar Yehuda. Targeting the A3 adenosine receptor for glaucoma treatment (Review).

Stemmer M, Benjaminov F, Medalia G, Ciuraru NB, Silverman MH, Bar-Yehuda S, Fishman S, Harpaz Z, Farbstein M, Cohen S, Patoka R, Singer B, Kerns WD, Fishman P. CF102 for the Treatment of Hepatocellular Carcinoma: A Phase I/II, Open-Label, Dose-Escalation

Pnina Fishman, Sara Bar-Yehuda, Bruce T. Liang and Kenneth A. Jacobson. Pharmacological and therapeutic effects of A3 adenosine receptor agonists.

Clara C. Blad, Jacobien K. von Frijtag Drabbe Künzel, Henk de Vries, Thea Mulder-Krieger, Sara Bar-Yehuda, Pnina Fishman, Adriaan P. IJzerman. Putative role of the adenosine A3 receptor in the antiproliferative action of N6-(2-isopentenyl)adenosine.

Sara Bar-Yehuda, Dror Luger, Avivit Ochaion, Shira Cohen, Renana Patokaa, Galina Zozulya, Phyllis B. Silver, Jose Maria Garcia Ruiz De Morales, Rachel R. Caspi, Pnina Fishman. Inhibition of experimental auto-immune uveitis by the A3 adenosine receptor ago

Ashar JN, Mathur A, Sangwan V. Avni I, Sliverman MH, Bar Yehuda S, Fishman P. CF101 for dry eye.

David M, Akerman L, Ziv M, Kadurina M, Gospodinov D, Pavlotsky, Yankova R, Kouzeva V, Ramon M, Silverman MH, Fishman P. Treatment of plaque-type psoriasis with oral CF101: data from an exploratory randomized phase 2 clinical trial.

Cohen S, Stemmer SM,Zozulya G, Ochaion A, Patoka R, Barer F, Bar-Yehuda S, Rath-Wolfson L, Jacobson KA, Fishman P. CF102 an A3 adenosine receptor agonist mediates anti-tumor and anti-inflammatory effects in the liver.

I. Avni, H. Garzozi, I. Barequet, F. Segev, D. Varssano, G. Sartani, N. Chetrit, E. Bakshi, D. Zadok, O. Tomkins, G. Litvin, K. Jacobson, S Fishman, Z. Harpaz, M. Farbstein, S. Bar Yehuda, M. Silverman, W. Kerns, D. Bristol, I Cohn, P. Fishman.

Fishman, P., Bar-Yehuda, S., Varani, K., Gessi, S., Merighi, S., and Borea, PA. Agonists and Antagonists: Molecular Mechanisms and Therapeutic Applications. In: P.A. Borea (ed.), A3 Adenosine Receptors from Cell Biology to Pharmacology and Therapeutics.

Fishman, P., Bar-Yehuda, S. Rheumatoid Arthritis: History, Molecular Mechanisms and Therapeutic Applications. P.A. Borea (ed.), A3 Adenosine Receptors from Cell Biology to Pharmacology and Therapeutics.

S. Bar-Yehuda, L. Rath-Wolfson, L. Del Valle, A. Ochaion, S. Cohen, R. Patoka, G. Zozulya, F. Barer, E. Atar, S. Pina-Oviedo, G. Perez-Liz, D. Castel,

P. Fishman, S. Bar-Yehuda, M. Synowitz, J.D. Powell, K.N. Klotz, S. Gessi, and P.A. Borea. Adenosine Receptors and Cancer.

A. Ochaion A, Bar-Yehuda S, Cohen S, Amital H, Jacobson KA, Joshi BV, Gao ZG, Barer F, Patoka R, Del Valle L, Perez-Liz G, Fishman P. The anti-inflammatory target A3 adenosine receptor is over-expressed in rheumatoid arthritis,

Bar-Yehuda S., Stemmer S.M., Madi L., Castel D., Ochaion A., Cohen S., Barer F., Zabutti A., Perez-Liz G., Del Valle L., Fishman P. The A3 adenosine receptor agonist CF102 induces apoptosis of hepatocellular carcinoma via de-regulation of the

Ochaion A, Bar-Yehuda S, Cohen S, Amital H, Jacobson KA, Joshi BV, Gao ZG, Barer F, Patoka R, Del Valle L, Perez-Liz G, Fishman P. The A3 adenosine receptor agonist CF502 inhibits the PI3K, PKB/Akt and NF-kappaB signaling pathway in synoviocytes from

Silverman M. H., Strand V., Markovits D., Nahir M., Reitblat T., Molad Y., Rosner I, Rozenbaum M., Mader R., Adawi M., Caspi D., Tishler M., Langevitz P., Rubinow A., Friedman J., Green L., Tanay A., Ochaion A., Cohen S., Kerns W. D., Cohn I.,

Bar Yehuda S., Silvermen M., Kerns W., Ochaion, A., Cohen, S., Fishman, P. The Anti-inflammatory Effect of A3 Adenosine Receptor Agonists: A Novel Targeted Therapy for Rheumatoid Arthritis.

Fishman P., Jacobson KA., Ochaion A., Cohen S., Bar Yehuda S. The Anti-Cancer Effect of A3 Adenosine Receptor Agonists: A Novel Targeted Therapy.

Madi L., Cohn, S. Ochaion A., Bar-Yehuda S., Barer F., Fishman P. Over-expression of A3 Adenosine Receptor in PBMNC of Rheumatoid Arthritis Patients: Involvement of NF-kB in mediating Receptor Level.

Fishman, P., Bar-Yehuda, S., Madi, L. In: Adenosine, Tumors, and Immunity. ADENOSINE RECEPTORS: Therapeutic Aspects for Inflammatory and Immune Diseases.

Ochaion A, Bar-Yehuda S, Cohn S, Del Valle L, Perez-Liz G, Madi L, Barer F, Farbstein M, Fishman-Furman S, Reitblat T, Reitblat A, Amital H, Levi Y, Molad Y, Mader R, Tishler M, Langevitz P, Zabutti A, Pnina Fishman. Methotrexate enhances the

Rath-Wolfson L., Bar-Yehuda S. Madi L., Fishman P. IB-MECA, an A3 adenosine receptor agonist prevents bone resorption in rats with adjuvant induced arthritis.

Fishman P., Bar-Yehuda S., Madi L., Rath-Wolfson L., Ochaion A., Cohen S. and Baharav E. The PI3K-NF-kB signal transduction pathway is involved in mediating the anti-inflammatory effect of IB-MECA in adjuvant induced arthritis.

Bar-Yehuda, S., Madi,L., Silberman, D., Slosman G., Shkapenuk, M., Fishman, P. CF101, an Agonist to the A3 Adenosine Receptor Enhances the Chemotherapeutic Effect of 5-Flurouracil in a Colon Carcinoma Murine Model.

Baharav, E., Bar-Yehuda, S., Madi, L., Silberman, D., Rath-Wolfson, L., Halpren, M., Ochaion, A., Weinberger, A., Fishman, P. The Anti-inflammatory Effect of A3 Adenosine Receptor Agonists in Murine Autoimmune Arthritis Models.

van Troostenburg, A. R., Clark, E. V., Carey, W. D. H., Warrington, S. J., Kerns, W.D., Cohn, I., Silverman, M. H., Bar-Yehuda, S., Fong, K.L. L., Fishman, P. Tolerability, pharmacokinetics, and concentration-dependent hemodynamic effects of oral CF101,

Madi, L., Ochaion, A., Rath-Wolfson, L., Bar-Yehuda, S., Erlanger, A., Ohana, G., Harish, A., Merimski, O., Barer, F., Fishman, P. The A3 Adenosine Receptor is Highly Expressed in Tumor vs. Normal Cells: Potential Target for Tumor Growth Inhibition.

Fishman, P., Bar-Yehuda, S., Ohana, G., Ochaion, A., Engelberg, A., Barer, F., Madi, L. An agonist to the A3 adenosine receptor inhibits colon carcinoma growth in mice via modulation of GSK-3ß and NF-kB.

Harish, A., Ohana, G., Fishman, P., Arnon, O., Bar-Yehuda, S. A3 Adenosine Receptor Agonist Potentiates Natural Killer Cell Activity.

Ohana, G., Bar-Yehuda, S., Arich, A., Madi L., Dreznick Z., Silberman D., Slosman G., Volfsson-Rath, L., Pnina Fishman. Inhibition of primary colon carcinoma growth and liver metastasis by the A3 adenosine receptor agonist.

Madi, L., Bar-Yehuda, S., Barer, F., Ardon, E., Ochaion, A., Fishman, P. A3 adenosine receptor activation in melanoma cells: association between receptor fate and tumor growth inhibition.

Fishman, P., Bar-Yehuda, S., Rath-Wolfson, L., Ardon, E., Barrer, F., Ochaion, A., Madi, L. Targeting the A3 adenosine receptor for cancer therapy: inhibition of Prostate carcinoma cell growth by A3AR agonist.

Merimsky O, Madi L, Bar-Yehuda S, Fishman P : Modulation of the A3 adenosine receptor by low agonist concentration induced anti-tumor and myelostimulation effects.

Fishman, P., Bar-Yehuda, S. Pharmacology and therapeutic applications of A3 receptor subtype.

Baharav, E., Dubrosin, A., Fishman, P., Bar-Yehuda, S., Halpern, M., Weinberger, A. Suppression of experimental zymosan induced arthritis by intraperitoneal administration of adenosine.

Bar-Yehuda, S., Madi, L., Barak, D., Mittelman, M., Ardon, E., Ochaion, A, Cohn, S., Fishman, P. Agonists to the A3 adenosine receptor induce G-CSF production via NF-kappaB activation: a new class of myeloprotective agents.

Fishman, P., Bar-Yehuda, S., Madi, L., Cohn, I. A3 adenosine receptor as a target for cancer therapy.

Fishman, P., Madi, L., Bar-Yehuda, S., Barer, F., Del Valle, L., Khalili, K. Evidence for involvement of Wnt signaling pathway in IB-MECA mediated suppression of melanoma cells.

Fishman, P., Bar-Yehuda, S., Barer, F., Madi, L., Multani, A.F, Pathak, S. The A3 adenosine receptor as a new target for cancer therapy and chemoprotection.

Ohana, G., Bar-Yehuda, S, Barer, F., Fishman, P. Differential effect of adenosine on tumor and normal cell growth: focus on the A3 adenosine receptor.

Fishman, P., Bar-Yehuda, S., Farbstein, T., Barer, F., Ohana, G. Adenosine acts as a chemoprotective agent by stimulating G-CSF production: a role for A1 and A3 adenosine receptors.

Fishman, P., Bar-Yehuda, S., Ohana, G., Pathak, S., Wasserman, L., Barer, F., Multani, A.F. Adenosine acts as an inhibitor of lymphoma cell growth: a major role for the A3 adenosine receptor.

Bar-Yehuda, S., Barer, F., Volfsson, L., Fishman, P. Resistance of muscles to tumor metastasis: a role for A3 adenosine receptor agonists.

Bar-Yehuda, S., Farbstein, T., Barer, F., Ohana, G., Fishman, P. Oral administration of muscle derived small molecules inhibits tumor spread while promoting normal cell growth in mice.

Fishman, P., Bar-Yehuda, S., Vagman, L. Adenosine and other low molecular weight factors released by muscle cells inhibit tumor cell growth.

Cohen-Aloro, D., Merimsky, O., Bar-Yehuda, S., Klein, B., Kayzer, S., Fishman, P. Mononuclear cells release low molecular weight factors with anti-cancer activity: A lower level of production by cells of cancer patients.

Djaldetti, M., Sredni, B., Zigelman, R., Verber, M., Fishamn, P. Muscle cells produce a low molecular weight factor with anti-cancer activity.